SENSEX NIFTY
Feb 25, 2013, 10.00 AM IST | Source: Reuters

Ranbaxy rises 4% on HSBC overweight report

HSBC raised its rating on shares of Ranbaxy Laboratories Ltd to 'overweight' from 'underweight' after the Indian drugmaker said it would resume production of a generic version of cholesterol fighter Lipitor for sale in the United States.

Ranbaxy rises 4% on HSBC overweight report

HSBC raised its rating on shares of Ranbaxy Laboratories Ltd to 'overweight' from 'underweight' after the Indian drugmaker said it would resume production of a generic version of cholesterol fighter Lipitor for sale in the United States.

HSBC added other factors behind its upgrade were share valuations after a recent correction, as well as the near-term catalysts such as the launch of additional generic drugs and the probability of a recovery in US sales.

Ranbaxy Labs' shares were up 4.22 percent to Rs 430.75 as of 9:58 am.

Ranbaxy Labs stock price

On October 31, 2014, Ranbaxy Laboratories closed at Rs 632.10, up Rs 8.35, or 1.34 percent. The 52-week high of the share was Rs 667.30 and the 52-week low was Rs 306.05.


The company's trailing 12-month (TTM) EPS was at Rs 20.93 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 30.2. The latest book value of the company is Rs 25.84 per share. At current value, the price-to-book value of the company is 24.46.

READ MORE ON  Ranbaxy Laboratories, HSBC
Set email alert for

ADS BY GOOGLE

video of the day

See 7% GDP by FY17; like pvt banks, autos: Kotak's Prasad

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.